Skip to main content
SpringerLink
Log in

Carboplatin and cisplatin: are they equivalent in efficacy in “optimal residual” advanced ovarian cancer?

  • Editorial
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Advanced Ovarian Cancer Trialists Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 303: 884–893

    Google Scholar 

  • Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10: 706–717

    Google Scholar 

  • Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P, Sheinfeld J, Russo P, Vlamis V, Carey R, Vogelzang NJ, Crawford ED, Bosl GJ (1993) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 11: 598–606

    Google Scholar 

  • Conte PF, Bruzzone M, Carnino F, Chiara S, Donadio M, Facchini V, Fioretti P, Foglia G, Gadducci A, Gallo L, Giaccone G, Guercio E, Iskra L, Janssen N, Maresi MP, Parodi G, Ragni N, Rosso R, Rubagotti A, Rugiati S, Storace A, Venturini S, Pescetto G (1991) Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: A randomized trial in stage III–IV epithelial ovarian carcinoma. J Clin Oncol 9: 658–663

    Google Scholar 

  • Mangioni C, Bolis G, Pecorelli, S, Bragman K, Epis A, Favalli G, Gambino A, Landoni F, Presti M, Torri W, Vassena L, Zanaboni F, Marsoni S (1989) Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 81: 1464–1471

    Google Scholar 

  • McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Davidson M for the Gynecologic Oncology Group (1995) Taxol and cisplatin improves outcome in advanced ovarian cancer as compared to cytoxan and cisplatin. Proc Am Soc Clin Oncol 14: 275

    Google Scholar 

  • Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, Kirk ME, Canetta R, Koski B, Shelley W, Zee B, Pater J (1992) Cisplatincyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10: 718–726

    Google Scholar 

  • Taylor AE, Wiltshaw E, Gore ME, Fryatt I, Fisher C (1994) Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 12: 2066–2070

    Google Scholar 

  • Vermorken JB, ten Bokkel Huinink WW, Eisenhauer EA, Favalli G, Belpomme D, Conte PF, Kaye SB (1993) Carboplatin versus cisplatin. Ann Oncol 4 (Suppl, 4): S41-S48

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195, Cleveland, Ohio, USA

    Maurie Markman

Authors
  1. Maurie Markman
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The “Journal of Cancer Research and Clinical Oncology” publishes in loose succession “Editorials” and “Guest editorials” on current and/or controversial problems in experimental and clinical oncology. These contributions represent exclusively the personal opinion of the authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. Carboplatin and cisplatin: are they equivalent in efficacy in “optimal residual” advanced ovarian cancer?. J Cancer Res Clin Oncol 122, 443–444 (1996). https://doi.org/10.1007/BF01187154

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01187154

Search

Navigation